Giaccone G, et al. - Pembrolizumab, a monoclonal antibody that targets PD-1, was tested for activity in patients with advanced thymic carcinoma. Based on findings, researchers concluded that pembrolizumab affords a promising treatment option in patients with thymic carcinoma. Careful monitoring is crucial due to more frequent occurrence of severe autoimmune disorders in thymic carcinoma than in other tumour types.